Lingrui Pharmaceutical released its 2026 interim report on August 12, 2026. The company's total operating revenue was 2.148 billion yuan, net profit attributable to the parent was 495 million yuan, and net cash inflow from operating activities was 723 million yuan. The latest asset-liability ratio was 43.19 percent, up 4.97 percentage points from the previous quarter. Gross margin was 78.90 percent, down 2.43 percentage points from the same period last year. ROE was 15.32 percent, down 0.15 percentage points from the same period last year. Diluted earnings per share was 0.87 yuan, total asset turnover was 0.38 times, and inventory turnover was 1.14 times. The number of shareholders was 41,300, and the top ten shareholders held 31.82 percent of the total share capital.
Henan Lingrui Pharmaceutical Co LtdInterim report shows net profit of 495 million yuan, indicating solid financial performance.
